Abstract
Aim:
To design and screen antisense oligodeoxynucleotides (ASODNs), which inhibit type-1 plasminogen activator inhibitor (PAI-1) expression in human umbilical vein endothelial cells (HUVEC) in vitro.
Methods:
Twenty seven ASODNs against different sites of PAI-1 mRNA were designed and transfected to HUVEC by lipofectin in vitro. The effects of ASODNs on PAI-1 antigen, PAI-1 activity and PAI-1 mRNA expression were detected by ELISA, amidolytical assay and RT-PCR, respectively.
Results:
Transforming growth factor β1(TGF-β1)-treated HUVEC increased the expression of PAI-1 compared with the normal HUVEC. Five among twenty seven designed ASODNs were effective in inhibiting the increase in PAI-1 antigen and PAI-1 activity in a dose-dependent manner after 48-h transfection. In particular, ASODN 14 (AO14) exhibited the best inhibitory effect. The control sequences of AO14, including sense, scramble, and mismatch sequences, did not significantly inhibit PAI-1 activity. It was revealed that the inhibitory efficacy of AO14 was in a sequence-specific manner. RT-PCR showed that ASODN 1, 7, 8, 14, and 15 decreased PAI-1 mRNA expression induced by TGF-β1 and AO14 showed the best inhibitory effect.
Conclusion:
ASODN 1, 7, 8, 14, and 15, among twenty seven designed ASODNs against PAI-1 mRNA, significantly decreased PAI-1 antigen and PAI-1 activity induced by TGF-β1 in a dose-dependent manner in HUVEC in vitro. AO14 showed the best inhibitory effect on PAI-1 expression in a sequence-specific manner. The results of RT-PCR indicated that inhibitory effects of ASODNs on PAI-1 biosynthesis occurred at the mRNA level. Four among five effective target sites of ASODNs located at the translation initiation site or within the translation area of PAI-1 mRNA, suggesting that these sites may be promising sites for the design of effective ASODNs.
Similar content being viewed by others
Article PDF
References
Aboul-Fadl T . Antisense oligonucleotides: the state of the art. Curr Med Chem 2005; 12: 2193–214.
Gleave ME, Monia BP . Antisense therapy for cancer. Nat Rev Cancer 2005; 5: 468–79.
Peyman A, Helsberg M, Kretzschmar G, Mag M, Grabley S, Uhlmann E . Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol Chem 1995; 376: 195–8.
Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D . Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2: 668–75.
Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B . The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res 2005; 116: 223–32.
Rupin A, Martin F, Vallez MO, Bonhomme E, Verbeuren TJ . Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb Haemost 2001; 86: 1528–31.
Liang A, Wu F, Tran K, Jones SW, Deng G, Ye B, et al. Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 2005; 115: 341–50.
Hasenstab D, Lea H, Clowes AW . Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol 2000; 20: 853–9.
Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673–80.
Mathews DH, Burkard ME, Ferier SM, Wgatt JR, Turner DH . Predicting oligonucleotide affinity to nucleic acid targets. RNA 1999; 5: 1458–69.
Stec WJ, Uznanski B, Wilk A, Hirschbein BL, Fearon KL, Bergot BJ . Bis(O,O-diisopropoxy phosphinothioyl) disulfide-a highly efficient sulfurizing reagent for cost-effective synthesis of oligo (nucleoside phosphothioate)s. Tetrahedron Lett 1993; 34: 5317–20.
Declerck PJ, Alessi MC, Werstreken M, Kruithof EKO, Juhan-Vague I, Collen D . Measurement of plasminogen activator inhibitor-1 (PAI-1) in biological fluids, with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220–5.
Eriksson E, Ranby M, Gyzander E, Risberg B . Determination of plasminogen activator inhibitor in plasma using tPA and a chro-mogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91–105.
Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G . A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res 1999; 27: 4328–34.
Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF . Antisense oligonucleotides inhibit intercellular adhesion molecular 1 expression by two distinct mechanisms. Biol Chem 1991; 266: 18162–71.
Biemond BJ, Levi M, Coronel R, Janse MJ, Van Care JW, Pannekoek H . Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody. Circulation 1995; 91: 1175–81.
Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA . Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2004; 2: 1422–8.
Eitzman DT, Fay PW, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416–20.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30271479) and National Hi-TECH research and development program of China (No 2001AA234041) and Post-doctor Science Foundation of China (No 2001-29).
Rights and permissions
About this article
Cite this article
Jiang, Qs., Wang, Sq. Design and screening of antisense oligodeoxynucleotides against PAI-1 mRNA in endothelial cells in vitro. Acta Pharmacol Sin 27, 1018–1023 (2006). https://doi.org/10.1111/j.1745-7254.2006.00367.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00367.x